Does PCA3 Really Help Urologists?

Although there is insufficient proof of improved health outcomes, expert opinions and Food and Drug Administration approval suggest a potential benefit of PCA3 use before considering repeat biopsy because the risk of undetected, clinically significant prostate cancer is low in cases of a low PCA3 score. Given that PCA3 may lead to a significant decrease in unnecessary biopsies, the cost-benefit balance of introducing PCA3 needs further assessment based on strict methodology incorporating health care outcomes.